TUBB4A and prostate adenocarcinoma: TUBB4A is amplified in 14% of neuroendocrine prostate cancers and 8% of castration-resistant prostate cancers but not in primary prostate adenocarcinomas, suggesting that genetic alteration of TUBB4A contributes to development of neuroendocrine and castration-resistant prostate cancers.